MIST — Milestone Pharmaceuticals Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1408443 ·
Last close
$0.79
Market Cap
$98.10M
52W High
$3.06
52W Low
$0.75
ADV30
1,571,453
Next earnings
2026-11-12

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 559,000 527,000 -25,630,000 -28,614,000 181,625,000 169,728,000 163,407,000
Mar 2026 238,000 224,000 -23,663,000 -26,066,000 193,734,000 71,317,000 157,685,000
Dec 2025 1,546,000 — -17,257,000 -17,409,000 113,561,000 73,046,000 71,792,000
Sep 2025 0 — -11,829,000 -11,922,000 87,750,000 46,685,000 67,249,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-51,142,000
Investing CF
$-102,367,000
Financing CF
$179,741,000
CapEx
$-341,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.83
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-456,669,000
Inventory
$1,826,000
Receivables
$5,001,000
ST Investments
$112,899,000
EBIT TTM
$-61,325,000
Pretax Income TTM
$-68,363,000
Interest Exp TTM
$7,038,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,343,000
EBITDA
$-78,207,000
Free Cash Flow
$-41,687,376
Enterprise Value
$109,329,776
Total Cash
$170,608,992
Total Debt
$141,832,000
Shares Out
124,497,980
Trailing EPS
$-0.65
Book Value
$0.13
ROE
-35522.6%
ROA
-42.8%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,546,000 -62,140,000 -63,058,000 113,561,000 71,792,000 41,769,000 -49,041,000
Dec 2024 0 -42,102,000 -41,519,000 75,499,000 62,352,000 13,147,000 -28,848,000
Dec 2023 1,000,000 -61,098,000 -59,685,000 75,226,000 58,455,000 16,771,000 -46,424,000
Dec 2022 5,000,000 -59,642,000 -58,388,000 74,483,000 8,135,000 66,348,000 -52,469,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.77

Max Pain — expiry 2026-12-18

max pain strike: $1.00 · spot: $0.80 · call oi: 3,677 · put oi: 526
Expected Move to 2026-12-18: ±$0.39 (48.72%) — implied range $0.41 – $1.19 · ATM straddle on $1.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
HSTC HST Global, Inc. $99.00M $0.70 —
RFL Rafael Holdings, Inc. $99.35M $1.94 —
ANIX Anixa Biosciences Inc $96.64M $2.78 —
BMEA Biomea Fusion, Inc. $95.44M $1.32 —
NTHI NEONC TECHNOLOGIES HOLDINGS, INC. $95.35M $3.31 —

News headlines (Yahoo Finance, 1h cache)

Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
2026-09-24 12:00 · Yahoo
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
2026-09-03 13:35 · Yahoo
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
2026-09-02 12:00 · Yahoo
Milestone Pharmaceuticals shares rise as first patient enters Phase 3 AFib trial
2026-08-21 13:28 · Yahoo
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
2026-08-21 12:00 · Yahoo
Milestone Pharmaceuticals Q2 Earnings Call Highlights
2026-08-12 15:04 · Yahoo
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates
2026-08-12 12:25 · Yahoo
Milestone Pharmaceuticals shares tumble after Q2 earnings miss
2026-08-12 12:04 · Yahoo
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST)
2026-07-29 13:35 · Yahoo
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-03 01:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.